BioCryst (BCRX) announced that it entered into a license agreement granting an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema in Europe. In exchange, BioCryst will receive $70M upfront and will be eligible to receive up to $275M in future regulatory and sales milestone payments. BioCryst will also receive tiered royalties on net sales ranging from 18% to 30%. The program is on track to support regulatory filing by the end of 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst Pharmaceuticals (BCRX) Q1 Earnings Cheat Sheet
- 3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
- BioCryst price target raised to $14 from $13 at RBC Capital
- BioCryst appoints Sandeep Menon as chief research and development officer
- EOG, GitLab, StoneCo, Cipher, BioCryst Insider Shake-Up